Nilesh Kumar
Research Subjects
Nilesh Kumar has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Ashish Sharma
Lotus Eye Hospital and Institute, Coimbatore, India
57 shared publications Nikulaa Parachuri
Aster Hospital, Dubai, UAE
45 shared publications- Francesco Bandello
Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy
43 shared publications Baruch D. Kuppermann
Gavin Herbert Eye Institute, University of California, Irvine, USA
38 shared publicationsAnat Loewenstein
24 shared publicationsBaruch D Kuppermann
Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, USA
10 shared publications
Latest Publications
- 10 December 2025
- Published by Springer Nature in Eye
Aflibercept vs ranibizumab biosimilars: manufacturing differences that might matter in the long run
- 10 December 2025
- Published by Springer Nature in Eye
Aflibercept vs ranibizumab biosimilars: manufacturing differences that might matter in the long run
- Open Access
- 25 June 2025
- Published by Elsevier in Journal of Medicine, Surgery, and Public Health
- Vol. 7
Botropase optimized conjunctival tissue grafting (BOT-Graft): Bridging efficacy, safety, and affordability in primary Pterygium surgery
- 25 June 2025
- Published by Elsevier in Journal of Medicine, Surgery, and Public Health
- Vol. 7
Open AccessBotropase optimized conjunctival tissue grafting (BOT-Graft): Bridging efficacy, safety, and affordability in primary Pterygium surgery
- 19 February 2025
- Published by Springer Nature in Eye
- Vol. 39 (6) , 1026-1027
Aflibercept 2 mg biosimilars—will they lead the Anti-VEGF biosimilar world globally
- 19 February 2025
- Published by Springer Nature in Eye
- Vol. 39 (6) , 1026-1027
Aflibercept 2 mg biosimilars—will they lead the Anti-VEGF biosimilar world globally
- 3 August 2024
- Published by Springer Nature in Eye
- Vol. 38 (17) , 3272-3278
Subfoveal neurosensory detachment flattening and observe (SNF-Ob) approach for the management of Ci-DMO - a multicentric study
Purpose To understand subfoveal neurosensory detachment flattening and observe (SNF-Ob) strategy and its relationship with visual acuity in the management of centre-involved diabetic macular oedema (Ci-DMO). Methods This was a multicentric retrospective observational study. We reviewed data of 188 eyes of 130 patients who presented with Ci-DMO with subfoveal neurosensory detachment (NSD) and treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents or steroids. The primary outcome was best corrected visual acuity (BCVA) measured at the time of the first subfoveal neurosensory detachment flattening (SNF) and at the end of follow-up. Results Eyes that achieved 20/50 (LogMAR = 0.40) or better at first SNF had mean LogMAR BCVA 0.38 ± 0.21, 0.24 ± 0.11 and 0.21 ± 0.15 at baseline, at the time of first SNF, and at the end of the last follow-up respectively. Mean LogMAR BCVA significantly improved from baseline to first SNF (p < 0.0001; 95% CI 0.115–0.183) and at the end of the last follow-up (p < 0.0001; 95% CI 0.126–0.213) with a change of Early Treatment Diabetic Retinopathy Study (ETDRS) 10 letters. There was no significant difference in improvement in BCVA from the first SNF and at the end of the last follow-up (p = 0.0781; 95% CI −0.002 to 0.046). Conclusions Eyes presenting with Ci-DMO and subfoveal NSD are unlikely to improve at SNF with BCVA > 20/50 (LogMAR = 0.40). Further evidence is needed before the combination of good BCVA and SNF may be considered as endpoint of pharmacological therapy for DMO.
- 3 August 2024
- Published by Springer Nature in Eye
- Vol. 38 (17) , 3272-3278
Subfoveal neurosensory detachment flattening and observe (SNF-Ob) approach for the management of Ci-DMO - a multicentric study
Purpose To understand subfoveal neurosensory detachment flattening and observe (SNF-Ob) strategy and its relationship with visual acuity in the management of centre-involved diabetic macular oedema (Ci-DMO). Methods This was a multicentric retrospective observational study. We reviewed data of 188 eyes of 130 patients who presented with Ci-DMO with subfoveal neurosensory detachment (NSD) and treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents or steroids. The primary outcome was best corrected visual acuity (BCVA) measured at the time of the first subfoveal neurosensory detachment flattening (SNF) and at the end of follow-up. Results Eyes that achieved 20/50 (LogMAR = 0.40) or better at first SNF had mean LogMAR BCVA 0.38 ± 0.21, 0.24 ± 0.11 and 0.21 ± 0.15 at baseline, at the time of first SNF, and at the end of the last follow-up respectively. Mean LogMAR BCVA significantly improved from baseline to first SNF (p < 0.0001; 95% CI 0.115–0.183) and at the end of the last follow-up (p < 0.0001; 95% CI 0.126–0.213) with a change of Early Treatment Diabetic Retinopathy Study (ETDRS) 10 letters. There was no significant difference in improvement in BCVA from the first SNF and at the end of the last follow-up (p = 0.0781; 95% CI −0.002 to 0.046). Conclusions Eyes presenting with Ci-DMO and subfoveal NSD are unlikely to improve at SNF with BCVA > 20/50 (LogMAR = 0.40). Further evidence is needed before the combination of good BCVA and SNF may be considered as endpoint of pharmacological therapy for DMO.
- 4 March 2024
- Published by Springer Nature in Eye
- Vol. 38 (10) , 1796-1798
Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs
- 4 March 2024
- Published by Springer Nature in Eye
- Vol. 38 (10) , 1796-1798
Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs
- Open Access
- 4 November 2023
- Published by Springer Nature in Eye
- Vol. 38 (5) , 824-825
Aflibercept biosimilars – update on the development progress
- 4 November 2023
- Published by Springer Nature in Eye
- Vol. 38 (5) , 824-825
Open AccessAflibercept biosimilars – update on the development progress
- 30 August 2023
- Published by Springer Nature in Eye
- Vol. 38 (2) , 244-245
Biosimilar anti-VEGF- is prefilled syringe (PFS) a challenge?
- 30 August 2023
- Published by Springer Nature in Eye
- Vol. 38 (2) , 244-245
Biosimilar anti-VEGF- is prefilled syringe (PFS) a challenge?
- 19 February 2023
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 23 (8) , 851-859
Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER – survey)
To assess the awareness of biosimilar intravitreal anti-vascular endothelial growth factor (VEGF) agents among retina specialists practicing in the United States (US) and Europe.A 16-question onlin...
- 19 February 2023
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 23 (8) , 851-859
Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER – survey)
To assess the awareness of biosimilar intravitreal anti-vascular endothelial growth factor (VEGF) agents among retina specialists practicing in the United States (US) and Europe.A 16-question onlin...
- 4 November 2022
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 31 (9) , 1746-1749
Immunogenicity: Clouding the Future of Intravitreal Therapy
The eye has classically been understood to be an immune-privileged organ, which means that immune reactions and subsequent inflammation do not occur in the eyes as frequently as the other organ sys...
- 4 November 2022
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 31 (9) , 1746-1749
Immunogenicity: Clouding the Future of Intravitreal Therapy
The eye has classically been understood to be an immune-privileged organ, which means that immune reactions and subsequent inflammation do not occur in the eyes as frequently as the other organ sys...